CHOLOVUE
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Aug 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CHOLOVUE is an injectable diagnostic agent developed by Bracco, approved in 1981 for diagnostic imaging purposes. The specific indication and mechanism of action are not publicly detailed in available data, but the product is positioned as an NDA-approved injectable formulation for imaging applications.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting declining team headcount and focus shift toward legacy management and transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and approaching LOE, career opportunities on CHOLOVUE are severely limited and unlikely to offer advancement or stability. Professionals should view assignments to this product as terminal roles focused on maximizing remaining revenue and managing market exit.
Product ManagerField Sales Representative
Worked on CHOLOVUE at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.